Menopausal syndrome as the first clinical manifestation of perimenopause

Authors

  • Т. Ф Татарчук Institute of Pediatrics, Obstetrics and Gynecology, NAMS of Ukraine, Ukraine
  • А. О. Исламова Institute of Pediatrics, Obstetrics and Gynecology NAM S of Ukraine, Ukraine
  • О. А. Ефименко Institute of Pediatrics, Obstetrics and Gynecology NAM S of Ukraine, Ukraine

DOI:

https://doi.org/10.18370/2309-4117.2015.21.52-56

Keywords:

climacteric syndrome, perimenopause, Kleverol, red clover

Abstract

A study to examine the efficacy and safety of drug Kleverol (active ingredient is a red clover) in patients with climacteric disorders of mild to moderate severity in late reproductive period was performed.

40 patients aged 36–49 years with climacteric disorders of mild to moderate severity were observed. Kleverol was administered 1 capsule a day for 3 months.

The average menopausal index, according to a Menopause Rating Scale (MRS), was significantly lower after treatment (8,7 ± 0,3) than before treatment (22,2 ± 0,3). In all examined women hormone levels corresponded to perimenopausal values. Side effects and individual intolerance reactions were not observed.

Authors of the study conclude that a good level of efficacy and safety Kleverol allows to use it at the earliest manifestations of menopausal disorders in women in the late reproductive period (perimenopause).

Author Biographies

Т. Ф Татарчук, Institute of Pediatrics, Obstetrics and Gynecology, NAMS of Ukraine

MD, professor, corresponding member. NAMS of Ukraine, Deputy Director for Research, Head of Endocrine Gynecology

А. О. Исламова, Institute of Pediatrics, Obstetrics and Gynecology NAM S of Ukraine

PhD, Endocrine Gynecology Department

О. А. Ефименко, Institute of Pediatrics, Obstetrics and Gynecology NAM S of Ukraine

PhD, senior researcher of the Endocrine Gynecology Department

References

  1. Andreeva, E.N. “Efficacy and tolerability of drugs for the treatment of menopausal disorders.” Gynecology, 2(2005): 109–110.
  2. Lykhatskyi, P.G., Fira, L.S. “Red clover as a promising drug.” Medical Chemistry, 2(7) (2005): 108–110.
  3. Medicine of menopause // Ed. by V.P. Smetnik. Moscow (2006): 848 p.
  4. Tatarchuk, T.F., Yefymenko, O.A. “Principles of diagnostics, prevention and treatment of menopausal disorders.” Journal of Ukrainian Medical Elite, 4(10) (2009): 24–29.
  5. Tatarchuk, T.F., Yefymenko, O.A. “Modern view at hormone therapy.” Reproductive endocrinology, 2(4) (2012): 34–39.
  6. Beck, V., Unterrieder, E., Krenn, L., Kubelka, W., Jungbauer, A. “Comparison of hormonal activity (estrogen, androgen, and progestin) of standardized plant extract for large scale use in hormone replacement therapy.” J of Steroid Biochem & Molecular Biology 1831(2003): 1–10.
  7. C leve, A., Fritzemeier, K.H., Haendler, B., et al. “Pharmacology and clinical use of sex steroid hormone receptor modulators.” Handb Exp Pharmacol, 214(2012): 543–587.
  8. Ying, C., et al. “Growth inhibition of human endothelial cells by the phytoestrogen biochanin A, a metabolite of genistein.” Br J Nutr, 85(5) (20001): 615–620.
  9. M enopause State of the art / Ed. by Iole Di Francesco (2011): 540 p.
  10. Scheider, H.P.G., Heinemann, L.A.J., Rosemeir, H.P., et al. “The menopause rating scale (MRS): reliability of scores of menopausal compleants.” Climacteric, 3(2000): 59–64.
  11. Yureneva, S.V., Ilina, L.M., Mullabaeva, S.M. “Skin and sex hormones (effects of menopause and hormone replacement therapy).” Plastic surgery and cosmetology, 4(2011): 512–522.

Published

2015-02-11

How to Cite

Татарчук, Т. Ф., Исламова, А. О., & Ефименко, О. А. (2015). Menopausal syndrome as the first clinical manifestation of perimenopause. REPRODUCTIVE ENDOCRINOLOGY, (21), 52–56. https://doi.org/10.18370/2309-4117.2015.21.52-56

Issue

Section

Management of menopause